CMP Therapeutics Appoints Dr Neill Moray Mackenzie as CEO

Posted On: August 4, 2010

CMP Therapeutics announces the appointment of Dr Neill Moray Mackenzie to the role of Chief Executive Officer. Dr Mackenzie brings to CMPT a long record of executive board level management within the biotechnology and pharmaceutical industries at companies including Cambridge Genetics Ltd, Oxford Biomedica plc (an LSE listed company), Avidex Ltd (now Immunocore) and most recently as the SVP for Business Development and Corporate Strategy at Medigene AG (a Borse-listed company) and CEO of Roji Ltd (London). In addition, Dr MacKenzie was formerly a Departmental Head in Vaccine R&D at Wellcome and a Wellcome Lecturer in Immunology at the University of London.

CMPT also announces the injection of a EUR1.5million convertible loan from Inventages Venture Capital to support continuing operations and the upcoming clinical trial of its lead product for the common cold. CMPT has been supported solely by investments from London-based Inventages Venture Capital and New Zealand-based BioPacificVentures since 2005.

CMP Therapeutics, founded in 2004, is a company that develops products for colds, flu and allergy based on b 1-3 N-acetyl glucosamine (chitin). b 1-3 N-acetyl glucosamine is extracted from natural sources. It is processed into micro-particles (Chitin Micro-Particles or CMP) under GMP manufacturing conditions. CMP is the active component. When administered intranasally it has been shown to be safe in man and effective in models of disease, including viral disease and bacterial diseases of the respiratory tract and allergy. CMP Therapeutics has worldwide patents and patent applications covering the uses and the manufacture of CMP for allergy, viral and bacterial disease, and as a vaccine adjuvant.

More info